PBH Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Revenue: $274.1 million, a decline of 3.4% year-over-year (from $283.8 million).
Adjusted EPS: $1.07, slightly down from $1.09 in the prior year but better than expectations.
Gross Margin: 55.7% for the first half, up 60 basis points year-over-year. Expected to reach 56.5% for the full year.
Free Cash Flow: $134 million for the first half, up 10% year-over-year. Full-year outlook remains at $245 million or more.
Leverage Ratio: Maintained at 2.4x with net debt around $900 million.

2. Strategic Updates and Business Highlights

E-commerce Growth: Continued double-digit growth in e-commerce consumption, attributed to prior investments and successful marketing strategies.
DenTek Brand Expansion: Focus on dental care products, particularly dental guards, which now hold over 50% market share. A successful marketing campaign linked to Fantasy Football has driven engagement and market share growth.
Acquisition Plans: Anticipation of acquiring Pillar5 for approximately $100 million, expected to close in Q3.

3. Forward Guidance and Outlook

Full-Year Revenue Guidance: Expected to be between $1.1 billion and $1.115 billion, with organic growth projected to decline by 1.5% to 3%.
Q3 Revenue Forecast: Approximately $282 million, down year-over-year due to inventory timing and e-commerce order adjustments.
Adjusted EPS Guidance: Full-year adjusted EPS expected to be between $4.54 and $4.58, with Q3 EPS anticipated at $1.14.

4. Bad News, Challenges, or Points of Concern

Supply Chain Issues: Ongoing constraints affecting Clear Eyes have led to lost market share and reduced shelf space at retailers.
Sales Declines: Notable declines in eye and ear care categories, as well as cough and cold products, which are expected to impact overall revenue.
Consumer Environment: Concerns about slowing consumer trends and potential impacts on consumption patterns, although the company feels insulated due to its focus on needs-based products.

5. Notable Q&A Insights

Clear Eyes Recovery: Management expects gradual improvement in Clear Eyes supply, with a focus on regaining lost shelf space and market share over the next two quarters.
E-commerce Variability: Unpredictable order patterns from e-commerce customers are a challenge, but the company remains focused on maintaining high service levels.
Marketing Investments: Future marketing spend will be evaluated based on product availability and market conditions, with a disciplined approach to capital allocation.
Private Label Competition: No significant change in competitive dynamics from private label products, which are focused on different market segments.

Overall, while PBH reported some challenges in the current quarter, particularly with supply chain constraints and market dynamics, the company remains optimistic about its long-term growth strategy and financial health.

PBH — Prestige Consumer Healthcare Inc.

Q2 2026 Earnings Call Summary